The present study focused on EGFR-mutant NSCLC patients who underwent sequential first- to third-generation EGFR-TKI treatment and evaluated the impact of sequential EGFR-TKI treatment on top-QTc. This evidence concerns the gene EGFR and non-small cell lung carcinoma.